Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo - PubMed (original) (raw)
. 2010 Oct 1;10(7):715-27.
doi: 10.4161/cbt.10.7.12926. Epub 2010 Oct 1.
Affiliations
- PMID: 20676039
- DOI: 10.4161/cbt.10.7.12926
Free article
Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo
Cara K Fraser et al. Cancer Biol Ther. 2010.
Free article
Abstract
The Src/Abl tyrosine kinase inhibitor dasatinib is an approved chronic myeloid leukemia treatment and is under investigation for solid tumor therapy. Members of the Src family of kinases (SFKs) are involved in the process of metastasis and dasatinib inhibits the migration and invasiveness of human melanoma cell lines in vitro. SFKs are also involved in immune function and angiogenesis, which both contribute to As active and passive immunotherapies continue to be investigated in metastatic melanoma, we investigated possible interactions between kinase inhibitors and immunotherapies. A murine syngenic model of metastatic melanoma in which B16F10 cells expressed ovalbumin (B16-OVA) was employed and the active immunotherapy comprised immunization with an OVA-expressing recombinant fowlpox virus (FPVOVA).Dasatinib did not affect B16-OVA viability, proliferation, migration or soft agar colony formation. However, depending on drug dose and schedule, differences in the metastatic behavior of B16-OVA were observed in vivo after dasatinib therapy. At a dose of 5 mg/kg/day given before tumor challenge, dasatinib therapy reduced the number of pulmonary metastases. Conversely, a higher dose (25 mg/kg/day), did not affect the number of pulmonary metastases and increased the number of extra-pulmonary metastases. Finally, immunization of B16-OVA-bearing mice with FPVOVA reduced the number of lung metastases. Prior treatment of these mice with dasatinib 5 mg/kg/day did not affect the incidence of lung metastases. Although the mechanisms by which dasatinib alters the metastatic behavior of B16-OVA cells in vivo remain to be determined, we hypothesize that dasatinib acts via multiple tumor-extrinsic processes that include immune function and neoangiogenesis.
Similar articles
- Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Fraser CK, et al. Exp Hematol. 2009 Feb;37(2):256-65. doi: 10.1016/j.exphem.2008.09.013. Epub 2008 Dec 3. Exp Hematol. 2009. PMID: 19056158 - Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Ortiz R, Díaz J, Díaz-Valdivia N, Martínez S, Simón L, Contreras P, Lobos-González L, Guerrero S, Leyton L, Quest AFG. Ortiz R, et al. Biochem Pharmacol. 2020 Jul;177:113941. doi: 10.1016/j.bcp.2020.113941. Epub 2020 Mar 30. Biochem Pharmacol. 2020. PMID: 32240650 - Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P, Zhang W, Gorlick R, Kolb EA. Hingorani P, et al. Clin Cancer Res. 2009 May 15;15(10):3416-22. doi: 10.1158/1078-0432.CCR-08-1657. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447875 - Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC, Seoane S, Ocaña A, Pandiella A. Montero JC, et al. Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Clin Cancer Res. 2011. PMID: 21670084 Review. - Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V. Gnoni A, et al. Curr Drug Targets. 2011 Apr;12(4):563-78. doi: 10.2174/138945011794751591. Curr Drug Targets. 2011. PMID: 21226671 Review.
Cited by
- Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.
Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, Ridder M, Guerrero-Setas D, Breckpot K, Escors D. Liechtenstein T, et al. Oncoimmunology. 2014 Jul 3;3(7):e945378. doi: 10.4161/21624011.2014.945378. eCollection 2014. Oncoimmunology. 2014. PMID: 25954597 Free PMC article. - Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
Pearlman RL, Montes de Oca MK, Pal HC, Afaq F. Pearlman RL, et al. Cancer Lett. 2017 Apr 10;391:125-140. doi: 10.1016/j.canlet.2017.01.029. Epub 2017 Jan 25. Cancer Lett. 2017. PMID: 28131904 Free PMC article. Review. - Use of gene expression and pathway signatures to characterize the complexity of human melanoma.
Freedman JA, Tyler DS, Nevins JR, Augustine CK. Freedman JA, et al. Am J Pathol. 2011 Jun;178(6):2513-22. doi: 10.1016/j.ajpath.2011.02.037. Am J Pathol. 2011. PMID: 21641377 Free PMC article. - Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Algazi AP, et al. Br J Cancer. 2012 Jan 3;106(1):85-91. doi: 10.1038/bjc.2011.514. Epub 2011 Nov 29. Br J Cancer. 2012. PMID: 22127285 Free PMC article. Clinical Trial. - Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge.
Singh S, Yang G, Schluns KS, Anthony SM, Sastry KJ. Singh S, et al. PLoS One. 2014 Mar 5;9(3):e90001. doi: 10.1371/journal.pone.0090001. eCollection 2014. PLoS One. 2014. PMID: 24599269 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous